• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Gen Fam Med . Seroprevalence of SARS-CoV-2 in Utsunomiya City, Greater Tokyo, after the first pandemic in 2020

tetano

Editor, Senior Moderator
J Gen Fam Med


. 2020 Dec 16;22(3):160-162.
doi: 10.1002/jgf2.408. eCollection 2021 May.
Seroprevalence of SARS-CoV-2 in Utsunomiya City, Greater Tokyo, after the first pandemic in 2020


Nobutoshi Nawa[SUP] 1 [/SUP], Jin Kuramochi[SUP] 2 [/SUP], Shiro Sonoda[SUP] 2 [/SUP], Yui Yamaoka[SUP] 3 [/SUP], Yoko Nukui[SUP] 4 [/SUP], Yasunari Miyazaki[SUP] 5 [/SUP], Takeo Fujiwara[SUP] 3 [/SUP]



Affiliations

Abstract

Background: A seroepidemiological study was conducted on a random sample of households in Utsunomiya City, Tochigi Prefecture, Greater Tokyo, Japan, to assess the seroprevalence of SARS-CoV-2.
Methods: The level of IgG antibodies in the blood of the recruited subjects was assessed using chemiluminescence immunoassay analysis. In addition, the population-based prevalence of SARS-CoV-2 was estimated.
Results: Three positive afebrile cases were confirmed. The estimated unweighted prevalence and weighted prevalence of SARS-CoV-2 infection were 0.40% and 1.23%, respectively.
Conclusions: This study suggests that the prevalence of SARS-CoV-2 may have been underestimated. Wider testing strategies may lead to revealing more SARS-CoV-2 cases.

Keywords: communicable diseases; coronavirus infections; seroepidemiologic studies.
 
Back
Top Bottom